昭衍新药(06127.HK)第三季度净利润为1977.37万元

Core Viewpoint - Zhaoyan New Drug (06127.HK) reported its Q3 2025 financial results, showing a revenue of 316 million yuan and a net profit of 19.77 million yuan, with basic earnings per share of 0.03 yuan [1] Financial Performance - For the first three quarters, the company achieved a total revenue of 985 million yuan and a net profit of 80.71 million yuan [1]